Inclusion Criteria:  Have signed the informed consent form; Participants of both genders aged ≥ 18 years; Report of snoring assessed objectively through the standardized criteria in the snoring noise domain in the Berlin questionnaire;  Exclusion Criteria:  History of allergy or hypersensitivity to the components of the nasal lubricant; Fixed nasal obstruction; Upper Airway Infections active or present for less than 7 days; Use of benzodiazepines and sleep inducing drugs; Under treatment for sleep apnea of any modality currently or within the past 6 months; Hepatic insufficiency; Active neoplastic disease; Severe sleep apnea determined by polysomnography (AHI > 30); Moderate sleep apnea with presence of excessive daytime sleepiness; Clinically significant illness or surgery, at the discretion of the principal investigator, within 30 days prior to study inclusion; History of chemical dependence or alcohol abuse; Any neurological and psychiatric disease or significant laboratory finding present, unless adequately controlled with medication allowed in the protocol; Patients with laboratory tests of SGOT, SGTP or CPK increased by at least two times the upper value of normal at the time of study inclusion; Women who are pregnant or breastfeeding or who have the desire to become pregnant; History of infarction and stroke; Craniofacial malformation; BMI > 35 Kg/m2; IDO ≥ 30 events/h determined in residence by Biologix®; Have symptoms of COVID-19 (fever, cold, loss of smell, loss of taste, dry cough, sore throat, diarrhea, difficulty breathing, fatigue, body aches and pains, headache).